{
    "clinical_study": {
        "@rank": "13429", 
        "arm_group": {
            "arm_group_label": "RA Patients on RoActemra/Actemra treatment"
        }, 
        "brief_summary": {
            "textblock": "This non-interventional study will observe the usage and efficacy of RoActemra/Actemra in\n      patients with rheumatoid arthritis (RA) who have recently begun treatment. The treatment\n      regimen will be directed by the treating physician according to clinical practice. Patients\n      are expected to be observed for approximately 6 months after beginning treatment."
        }, 
        "brief_title": "Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients at least 18 years of age\n\n          -  Patients with a diagnosis of moderate to severe RA according to the revised (1987)\n             ACR criteria\n\n          -  Patient in whom the treating physician has made the decision to commence\n             RoActemra/Actemra treatment (in accordance with the local label).  This can include\n             patients who have received RoActemra/Actemra treatment within 8 weeks prior to the\n             enrolment visit\n\n          -  Patient has given informed consent\n\n        Exclusion Criteria:\n\n          -  Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment\n             visit\n\n          -  Patients who have previously received RoActemra/Actemra in a clinical trial or for\n             compassionate use\n\n          -  Patients who have received treatment with any investigational agent within 4 weeks\n             (or 5 half-lives of investigational agent, whichever is longer) before starting\n             treatment with RoActemra/Actemra\n\n          -  Patients with a history of autoimmune disease or of any joint inflammatory disease\n             other than RA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients with rheumatoid arthritis starting RoActemra/Actemra treatment"
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101307", 
            "org_study_id": "ML28429"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100034"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100083"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chang Sha", 
                        "country": "China", 
                        "zip": "410008"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "zip": "610072"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "HangzhouZhejiang", 
                        "country": "China", 
                        "zip": "310009"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "zip": "710032"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "zip": "710061"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xinjiang Urumqi", 
                        "country": "China", 
                        "zip": "830001"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28429 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients on RoActemra/Actemra treatment 6 months after treatment initiation", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101307"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients with systemic manifestation of RA", 
                "safety_issue": "No", 
                "time_frame": "At Baseline"
            }, 
            {
                "measure": "Record of RA treatment history", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Treatment patterns during observation period, assessed by alteration in dosing regimen", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Efficacy as assessed by total joint count evaluation", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Health-related quality of life as assessed by questionnaire", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}